If such a lymphopenia is indeed regulating T cell activation and driving the expansion of cytokine-producing T cell subsets, then these findings may have serious implications for the treatment with dual pharmacological inhibitors of p110γ and p110δ. Here, PIK3CD is linked to lymphopenia.